Aims: To evaluate short-term clinical outcomes following transcatheter aortic valve implantation (TAVI) using CE-mark approved devices in Switzerland.
Peter Wenaweser1*, MD; Stefan Stortecky1, MD; Dik Heg2, PhD; David Tueller3, MD; Fabian Nietlispach4, MD; Volkmar Falk4, MD; Giovanni Pedrazzini5, MD; Raban Jeger6, MD; Oliver Reuthebuch6, MD; Thierry Carrel1, MD; Lorenz Räber1, MD; Franz W. Amann7, MD; Enrico Ferrari8, MD; Stefan Toggweiler9, MD; Stephane Noble10, MD; Marco Roffi10, MD; Jürg Gruenenfelder11, MD; Peter Jüni2, MD; Stephan Windecker1, MD; Christoph Huber
1. Department of Cardiology and Department of Cardiovascular Surgery, Swiss Cardiovascular Centre, Bern University Hospital, Bern, Switzerland; 2. Department of Clinical Research, Clinical Trials Unit, University of Bern, Bern, Switzerland; 3. Triemli Hos
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
aortic stenosisoutcomestranscatheter aortic valve implantation
Read next articleThe challenge of valve-in-valve procedures in degenerated Mitroflow bioprostheses and the advantage of using the JenaValve transcatheter heart valve